National Cerebral and Cardiovascular Center’s Post

“In the search for meaningful and effective treatment methods, researchers also consider transcranial pulse stimulation to be a means of choice for targeted and/or supportive treatment of neuro-covid. Within the framework of the healing trial* recognized in Germany, the TPS therapy was able to show in meanwhile 200 (as of January 2023) neuro-covid patients that their symptomatology could be significantly reduced after mostly only three individual treatments with the TPS therapy and led to general freedom from symptoms. Due to the mechanisms of action on the human brain, this therapy approach is also only logical for Neuro-Covid. Currently, scientific working groups are working intensively on transcranial pulse stimulation in Long-Covid and Neuro-Covid and it is already clear that we will be able to issue an even clearer therapy recommendation with meaningful and validatable data by the end of the quarter 2023.” Prof. Musa Citak, M.D.

In the early '90s, the BBB hypothesis was the belle of the scientific ball until the amyloid hypothesis cut in, sweeping researchers off their feet. Fast forward a few decades, and it turns out the amyloid hypothesis might just be the charming fraud at the dance. Looks like it's time to dust off those old records from 35 years ago and give the BBB hypothesis another spin. Oh, the cycles of scientific nostalgia! Thank you Yulia Ilina for this post. #alzheimer #neuroscience #dementia #neurology

Multivitamin-mineral supplements are Effective!!!! What a surprise? "Effect of multivitamin-mineral supplementation versus placebo on cognitive function: results from the clinic subcohort of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial and meta-analysis of 3 cognitive studies within COSMOS" https://lnkd.in/e8qRyhMC "Conclusions In COSMOS-Clinic, daily MVM supplementation leads to a significantly more favorable 2-y change in episodic memory. The meta-analysis within COSMOS cognitive substudies indicates that daily MVM significantly benefits both global cognition and episodic memory. These findings within the COSMOS trial support the benefits of a daily MVM in preventing cognitive decline among older adults."

🧠 This study by Tian et al. examines the correlation between increased blood-brain barrier (BBB) permeability and the risk of progressive cognitive decline. It utilizes the cerebrospinal fluid/serum albumin ratio (QAlb) as a marker within a clinical cohort to assess BBB integrity and its relationship to cognitive deterioration over time. 🔬 Study Design: The research was conducted as a prospective observational cohort study involving 295 participants. It investigated the association between BBB permeability and the progression of cognitive impairment, employing neuropsychological assessments and continuous medical monitoring over an average period of 17 months. 💡 Key findings: 🕐 Elevated BBB permeability, indicated by high QAlb levels, correlates significantly with cognitive decline. This finding is particularly pronounced in patients with Alzheimer's disease (AD) compared to those with milder cognitive impairments (MCI) or subjective cognitive decline (SCD). 🕑 The presence of the APOE 4 allele and conditions like diabetes mellitus are associated with increased BBB permeability, highlighting potential risk factors that could predispose individuals to faster cognitive decline. 🕒 The study suggests that addressing BBB dysfunction may provide a new avenue for therapeutic intervention, potentially slowing the progression of cognitive impairment in affected individuals. For more details: https://lnkd.in/dDhc5Abb #CognitiveDecline #BloodBrainBarrier #Neurology #ClinicalResearch

📣📣📣Newly published article sharing! Neuroprotective prospectives of triterpenoids ✍ Apoorva A. Bankar, Vaishali P. Nagulwar, Nandkishor R. Kotagale, Nazma N. Inamdar Explor Neurosci. 2024;3:231–254  DOI: https://lnkd.in/garWYKhS Abstract: Neurological disorders including neurodegenerative disorders continue to pose significant therapeutic challenges. Triterpenoids, a diverse group of natural compounds found abundantly in plants, possess promising neuroprotective properties. This review aims to explore the potential of triterpenoids in mitigating neurodegeneration through various mechanisms, including antioxidant, anti-inflammatory, and anti-apoptotic activities. The neuroprotective potential of some notable triterpenoids, such as asiatic acid, asiaticoside, madecassoside, bacoside A, bacopaside I, ganoderic acids, and lucidenic acids are discussed in terms of their ability to modulate key pathways implicated in neurological disorders. Additionally, the potential therapeutic applications of triterpenoids in Alzheimer’s disease, Parkinson’s disease, cerebral ischemia, spinal cord injury, and epilepsy are examined. Furthermore, the review also underlines the challenges for the development of triterpenoids as neuroprotective agents, including the need for further preclinical and clinical studies to elucidate their efficacy and safety for translation into clinical practice. Welcome to read!

Happy to share our newest publication: Inflammatory biomarkers for neurobehavioral dysregulation in former American football players: findings from the DIAGNOSE CTE Research Project, published in Journal of Neuroinflammation. In a cohort of former American football players, we found an association between elevated levels of IL-6 in cerebrospinal fluid and neurobehavioral dysregulation symptoms (i.e., emotional dyscontrol, affective lability, impulsivity). In older former players, we also found that higher levels of plasma neurofilament light were associated with these behavioral symptoms, but also with worse executive functioning. These results collectively show that neurobehavioral dysregulation among former American football players may be associated with an altered neuroinflammatory response and that, in later life, specific behavioral symptoms may be part of a broader clinical syndrome that potentially involves both neuroinflammation and neurodegeneration. This project was part of my research fellowship at the Boston University CTE Center and the DIAGNOSE CTE Research Project. A big shout out to all coauthors and coordinating staff of the project. Special thanks to Robert Stern for being a fantastic mentor in all this! https://lnkd.in/eBNjUYBc  

Rebalancing the ECS May Improve Cognitive Impairment A study examining neurons from the hippocampus, a critical area of memory, suggests that increasing endocannabinoids could relieve cognitive deficits caused by decreased blood flow and oxygen exchange. This improvement appears to be linked to the restoration of CB2-dependent endoplasmic reticulum stress and mitochondrial dysfunction. The research highlights the cannabinoid receptor 2 (CB2) as a promising therapeutic target for the treatment of ischemic cerebrovascular conditions. Source: Wang DP, Kang K, Hai J, Lv QL, Wu ZB. Alleviating CB2-Dependent ER Stress and Mitochondrial Dysfunction Improves Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment. J Neuroimmune Pharmacol. 2024 Jan 12;19(1):1. doi: 10.1007/s11481-024-10098-x. PMID: 38214766; PMCID: PMC10786746. https://lnkd.in/gnhJKetM

📃Scientific paper: Thyroid Hormone Augmentation for Bipolar Disorder: A Systematic Review Abstract: Thyroid hormone (TH) augmentation, although commonly used for major depression, is sparingly used for bipolar disorder (BD) after the failure of mood-stabilizing agents. While the exact mechanisms of thyroid hormone action in BD remains unclear, central thyroid hormone deficit has been postulated as a mechanism for rapid cycling. This systematic review—conducted in accordance with the PRISMA guidelines—of eight studies synthesizes the evidence for TH augmentation in BD. A systematic search of the Ovid MEDLINE, Embase, PsycINFO, and Cochrane databases was conducted for randomized controlled trials (RCT), open-label trials, and observational studies of levothyroxine (LT4) and triiodothyronine (T3) for BD. Open-label studies of high dose LT4 augmentation for bipolar depression and rapid cycling showed improvement in depression outcomes and reduction in recurrence, respectively. However, an RCT of high-dose LT4 did not show benefit in contrast to placebo. An RCT comparing LT4, T3, and placebo showed benefit only in rapid-cycling bipolar women. A meta-analysis could not be completed due to significant differences in study designs, interventions, and outcomes. Our systematic review shows mixed evidence and a lack of high-quality studies. The initial promise of supratherapeutic LT4 augmentation from open-label trials has not been consistently replicated in RCTs. Limited data are available for T3. The studies did not report significant thyrotoxicosis, and TH augmentation... Continued on ES/IODE ➡️ https://etcse.fr/zRt5 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

🎉 Exciting News! 🎉 I'm thrilled to share my latest article, published today! Using cellular models in case study patients, I aimed to explore the interplay between mitochondrial function and major depression. Key highlights include: • Enriching the bioenergetics hypothesis of depression, moving beyond a strict decrease in function to a more nuanced view that includes overactivation of certain functions, creating a detrimental imbalance • Providing evidence to support the hypothesis that mitochondria play a crucial role in the pathophysiology of depression • Observing consistently decreased cell size, suggesting this could be a marker for mitochondrial dysfunction and inform future diagnostic and therapeutic approaches A big thanks to my co-authors, especially my mentor Prof. Christian Wetzel, my students Sonja Grobecker and Selin Küçükoktay and my dear colleague Stefanie Bader. You can access the full article titled "Mitochondrial and Cellular Function in Fibroblasts, Induced Neurons, and Astrocytes Derived from Case Study Patients: Insights into Major Depression as a Mitochondria-Associated Disease" here: https://lnkd.in/edP59JbU MDPI Stay tuned for a follow-up article on the effects of a chronic serotonin treatment on iPS-derived astrocytes and neurons. #depression #majordepressivedisorder #treatmentresistantdepression #mitochondria #research #mdpiopenaccess